The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.

Vera Therapeutics reports $10.3 million TRUTAKNA revenue in first partial quarter

Nov 7, 2026 08:09 (2d ago)

Verifying

Vera Therapeutics reported $10.3 million in third-quarter TRUTAKNA net product revenue.
Vera recorded a $93.7 million net loss, or $1.30 per share, in Q3 2026.
The company submitted a supplemental BLA for full approval in October 2026.